Bristol Myers Squibb

FDA approves Bristol Myers Squibb's advanced multiple myeloma treatment, debuting a new drug class.

FDA approves Bristol oral treatment for advanced multiple myeloma, debuting a new drug class.

AstraZeneca stock declined on reports of merger talks with Bristol Myers Squibb, while a revised 340B plan indicates ongoing regulatory changes in drug pricing.